The global surge in GLP-1 receptor agonist therapies for obesity and Type 2 diabetes has transformed the requirements for subcutaneous drug delivery. Unlike daily insulin routines, once-weekly weight-management regimens demand a sleek, intuitive, and patient-centric device that minimizes injection anxiety. The V3 GLP-1 Injection Pen is purpose-built to meet these evolving clinical and lifestyle demands.
Featuring a built-in assist-spring mechanism and an ergonomic profile, the V3 platform delivers high-viscosity formulations effortlessly, ensuring optimal adherence across multi-week dosing schedules.
Core Features of the V3 GLP-1 Injection Pen
Assisted Spring Injection Mechanism: Stores kinetic energy during dose selection to provide automatic, low-effort plunger advancement, reducing thumb push-force by up to 40%.
Optimized for Step-Up Titration: Engineered with preset fixed steps (e.g., 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg) or standard unit dials, perfectly aligning with clinical GLP-1 dose escalation protocols.
Large Magnified Viewing Window: High-contrast, wide-angle lens ensures users can easily confirm selected doses and monitor remaining liquid levels.
Dual Audible & Tactile Feedback: Emits distinct mechanical clicks at the start and completion of injection, ensuring patients do not remove the needle prematurely.
Discreet Lifestyle Aesthetic: Contemporary soft-touch contours designed to feel like a modern wellness device rather than a clinical tool.
Technical Specifications
| Parameter | Specification |
| Product Model | V3 Ergonomic GLP-1 Injection Pen |
| Compatible Cartridges | Standard 3.0 ml Glass Cartridges (ISO 13926-1) |
| Dose Escalation Presets | Fixed Multi-Dose (0.25mg / 0.5mg / 1.0mg / 2.0mg) or Step Dials |
| Injection Actuation | Spring-Assisted Push-Button Delivery |
| Glide Force Reduction | ~40% lower push resistance vs. standard manual pens |
| Needle Compatibility | Universal ISO 11608-2 pen needles (31G – 34G ultra-fine) |
| Housing Material | Medical-Grade Polycarbonate & Soft-Touch Elastomer |
| Certifications & Standards | ISO 11608-1/2/3, ISO 13485, CE MDR, FDA Ready |
Therapeutic Applications
The V3 platform is the delivery device of choice for modern metabolic and endocrine treatments:
Obesity & Weight Management: Weekly GLP-1 receptor agonist therapies (Semaglutide, Tirzepatide, and peptide analogs).
Type 2 Diabetes Care: Long-acting basal GLP-1/insulin combination therapies.
Cardiometabolic Therapies: Self-administered preventative biologics requiring consistent monthly/weekly schedules.
Comprehensive OEM/ODM Manufacturing for Pharmaceutical Brands
We provide end-to-end contract manufacturing to help pharmaceutical companies launch generic and branded GLP-1 drug-device combination products:
Custom Step-Dose Calibration: Factory-calibrated gear sets customized for your proprietary drug concentration and titration steps.
Color-Coded Strength Variants: Distinct pen cap and dial colors to clearly differentiate dosage tiers and prevent patient medication errors.
Scalable Cleanroom Production: Fully automated Class 100,000 cleanroom assembly ensuring high batch-to-batch repeatability.
Full Regulatory Filing Support: Comprehensive design files, biocompatibility testing (ISO 10993), and risk analysis documentation.
Frequently Asked Questions (FAQ)
Q: Can the V3 pen be customized for a 4-dose monthly GLP-1 cycle?
A: Yes. The internal drive mechanism can be configured specifically for standard 4-dose monthly treatment schedules with mechanical end-of-dose lockouts.
Q: Does the assist-spring mechanism require manual cocking?
A: No. The internal spring is charged automatically as the user dials the dose, ensuring a seamless one-step preparation process.